TABLE 6.

Impact of carbapenem resistance in Acinetobacter spp. on mortality, LOS, and hospital costs

Type of study showing an impact of resistanceSettingInfectionNo. of cases/no. of controlsParameterMain findingsSignificance (P value or 95% CI)Reference
Case-controlTertiary careNosocomial10/10MortalityCases, 34%; controls, 27% P > 0.05 9
LOSCases, 31.5 days; controls, 13 days P = 0.02
Case-controlTertiary careBurn patients34/43MortalityCases, 26.5%; controls, 0% P < 0.01 82
LOSCases, 32.5 days; controls 21 days P < 0.01
Case-controlTertiary careBurn patients34/183LOSCases, 36.8 days; controls, 25.6 days P = 0.06 81
CostCases, $98,575 higher P < 0.01
Case-controlTertiary careBSI40/40aMortalityCases, 57.5%; controls, 25.7% P = 0.007 39
Case-controlICUNosocomial infections34/68aMortalityOR,b 3.91.4-10.7 61
LOSCases, 30 days longer11-38 days
Case-controlICUColonization32/63aLOS (ICU)Cases, 19 days longer5-28 days 61
  • a Studies with either matched controls or multivariate analysis, in order to minimize confounding.

  • b OR, odds ratio.